395 related articles for article (PubMed ID: 29685879)
21. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
22. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
Van Bockstal MR; Agahozo MC; Koppert LB; van Deurzen CHM
Int J Cancer; 2020 Mar; 146(5):1189-1197. PubMed ID: 31018242
[TBL] [Abstract][Full Text] [Related]
23. Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis.
Rakovitch E; Nofech-Mozes S; Narod SA; Hanna W; Thiruchelvam D; Saskin R; Taylor C; Tuck A; Sengupta S; Elavathil L; Jani PA; Done SJ; Miller N; Youngson B; Kong I; Paszat L
Breast Cancer Res Treat; 2013 Apr; 138(2):581-90. PubMed ID: 23456231
[TBL] [Abstract][Full Text] [Related]
24. Multigene Expression Assay and Benefit of Radiotherapy After Breast Conservation in Ductal Carcinoma in Situ.
Rakovitch E; Nofech-Mozes S; Hanna W; Sutradhar R; Baehner FL; Miller DP; Fong C; Gu S; Tuck A; Sengupta S; Elavathil L; Jani PA; Bonin M; Chang MC; Slodkowska E; Anderson JM; Cherbavaz DB; Shak S; Paszat L
J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 30053207
[TBL] [Abstract][Full Text] [Related]
25. Estrogen-receptor status and risk of contralateral breast cancer following DCIS.
Stout NK; Cronin AM; Uno H; Ozanne EM; Hassett MJ; Frank ES; Greenberg CC; Punglia RS
Breast Cancer Res Treat; 2018 Oct; 171(3):777-781. PubMed ID: 29946862
[TBL] [Abstract][Full Text] [Related]
26. Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.
Schmitz RSJM; van den Belt-Dusebout AW; Clements K; Ren Y; Cresta C; Timbres J; Liu YH; Byng D; Lynch T; Menegaz BA; Collyar D; Hyslop T; Thomas S; Love JK; Schaapveld M; Bhattacharjee P; Ryser MD; Sawyer E; Hwang ES; Thompson A; Wesseling J; Lips EH; Schmidt MK;
BMJ; 2023 Oct; 383():e076022. PubMed ID: 37903527
[TBL] [Abstract][Full Text] [Related]
27. Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
Byng D; Retèl VP; Schaapveld M; Wesseling J; van Harten WH;
Breast Cancer Res Treat; 2021 May; 187(1):187-196. PubMed ID: 33389397
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.
Almekinders MM; Bismeijer T; Kumar T; Yang F; Thijssen B; van der Linden R; van Rooijen C; Vonk S; Sun B; Parra Cuentas ER; Wistuba II; Krishnamurthy S; Visser LL; Seignette IM; Hofland I; Sanders J; Broeks A; Love JK; Menegaz B; Wessels L; Thompson AM; de Visser KE; Hooijberg E; Lips E; Futreal A; Wesseling J;
Br J Cancer; 2022 Oct; 127(7):1201-1213. PubMed ID: 35768550
[TBL] [Abstract][Full Text] [Related]
29. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
[TBL] [Abstract][Full Text] [Related]
30. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
31. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
32. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.
Solin LJ; Gray R; Hughes LL; Wood WC; Lowen MA; Badve SS; Baehner FL; Ingle JN; Perez EA; Recht A; Sparano JA; Davidson NE
J Clin Oncol; 2015 Nov; 33(33):3938-44. PubMed ID: 26371148
[TBL] [Abstract][Full Text] [Related]
33. Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy.
Rakovitch E; Nofech-Mozes S; Hanna W; Sutradhar R; Gu S; Fong C; Tuck A; Youngson B; Miller N; Done SJ; Chang MC; Sengupta S; Elavathil L; Jani PA; Bonin M; Lalani N; Paszat L
Breast; 2018 Feb; 37():181-186. PubMed ID: 28781102
[TBL] [Abstract][Full Text] [Related]
34. Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation.
Punglia RS; Cronin AM; Uno H; Stout NK; Ozanne EM; Greenberg CC; Frank ES; Schrag D
JAMA Oncol; 2017 Jan; 3(1):101-104. PubMed ID: 27442038
[TBL] [Abstract][Full Text] [Related]
35. Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ.
Miller ME; Muhsen S; Zabor EC; Flynn J; Olcese C; Giri D; Van Zee KJ; Pilewskie M
Ann Surg Oncol; 2019 Dec; 26(13):4317-4325. PubMed ID: 31552614
[TBL] [Abstract][Full Text] [Related]
36. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
37. Endocrine Therapy Initiation and Medical Oncologist Utilization Among Women Diagnosed with Ductal Carcinoma in Situ.
Anderson C; Meyer AM; Wheeler SB; Zhou L; Reeder-Hayes KE; Nichols HB
Oncologist; 2017 May; 22(5):535-541. PubMed ID: 28408621
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological predictive factors for ipsilateral and contralateral events following initial surgery to treat ductal carcinoma in situ.
Tamura N; Tsuda H; Yoshida M; Hojo T; Akashi-Tanaka S; Kinoshita T; Sugihara K
Breast Cancer; 2016 May; 23(3):510-8. PubMed ID: 25666939
[TBL] [Abstract][Full Text] [Related]
39. Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.
Pawloski KR; Tadros AB; Sevilimedu V; Newman A; Gentile L; Zabor EC; Morrow M; Van Zee KJ; Kirstein LJ
Breast Cancer Res Treat; 2021 Apr; 186(3):617-624. PubMed ID: 33675490
[TBL] [Abstract][Full Text] [Related]
40. Characterization and treatment of local recurrence following breast conservation for ductal carcinoma in situ.
Greenberg CC; Habel LA; Hughes ME; Nekhlyudov L; Achacoso N; Acton L; Schrag D; Jiang W; Edge S; Weeks JC; Punglia RS
Ann Surg Oncol; 2014 Nov; 21(12):3766-73. PubMed ID: 24859938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
